“Poseida is developing a promising next generation CAR-T cell therapy which includes many of the desirable attributes of emerging CAR-T cell therapies into a single treatment,” Maria Millan, MD, president and chief executive officer of CIRM, said in a press release. “CIRM is pleased to support Poseida in the development of this novel CAR-T therapy which represents a much-needed solution for multiple myeloma.”

P-BCMA-101 is a chimeric antigen receptor (CAR) T-cell therapy. This is a tailored approach to fight cancer in which researchers use a patient’s own T-cells, which are vital cells of the immune system. These cells are collected from the patient’s blood and taken to the lab, where they are engineered to express, at their surface, special receptors called CARs.

CARs allow T-cells to recognize a specific protein (antigen) that is highly produced by tumor cells. The re-engineered T-cells are then expanded in the lab into the billions and injected back into the patient, where they will attack tumor cells more efficiently.

P-BCMA-101 targets a specific antigen called B-cell maturation antigen (BCMA) that is expressed by all multiple myeloma cells. But unlike many other CAR T-cell therapies, P-BCMA-101 delivers the CAR gene to the T-cells using a non-viral gene delivery system. This system has a number of advantages, including the production of T-cells with stem cell memory, the selection of engineered cells, and safety.

Because P-BCMA-101 contains a high number of stem cell memory T-cells, patients have sustained responses and do not require additional infusions of the therapy, as shown in multiple preclinical studies.

In CAR T-cell therapies, only 5% to 30% of the reinfused T-cells were actually genetically modified. But with the positive selection tool included in Poseida’s gene delivery system, researchers can select only the modified cells, ensuring that their cell therapy is 100% pure. Also, P-BCMA-101’s safety is ensured by a backup mechanism — T-cells are rapidly shut down if significant side effects occur.

“We are honored that CIRM has recognized the promise of P-BCMA-101 as an immunotherapy for patients with multiple myeloma and is contributing to the advancement of this program in Phase 1 clinical development,” said Eric Ostertag, MD, PhD, Poseida’s chief executive officer. “P-BCMA-101 is elegantly designed with several key characteristics, including an exceptionally high concentration of stem cell memory T-cells which has the potential to significantly improve durability of response to treatment.”

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

Disclaimer:

Myeloma Research News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.

Pin It on Pinterest

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. We never use your cookies for creepy ad retargeting that follows you around the web. OkRead more